LLY | tickerfilter.com

Fundamental analysis

59%

Profitability 75%

Dept financing 22%

Liquidity 37%

Performance 57%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-0.85%

1 Month

-3.70%

3 Months

-2.69%

6 Months

32.36%

1 Year

21.66%

2 Year

32.44%

Key data

Stock price

$999.84

P/E Ratio

46.82

DAY RANGE

$990.30 - $1,002.93

EPS

$23.00

52 WEEK RANGE

$623.78 - $1,133.95

52 WEEK CHANGE

$24.72

MARKET CAP

966.460 B

YIELD

0.56%

SHARES OUTSTANDING

943.357 M

DIVIDEND

$1.73

EX-DIVIDEND DATE

02-13-2026

NEXT EARNINGS DATE

08-07-2025

BETA

0.81

PUBLIC FLOAT

AVERAGE 10 VOLUME

$2,525,953

AVERAGE 30 VOLUME

$2,919,020

Company detail

CEO: David A. Ricks
Region: US
Website: lilly.com
Employees: 39,000
IPO year: 1972

Issue type: Common Stock
Market: NYSE
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic colorectal cancer, and hepatocellular carcinoma. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic ax

LLY - ELI LILLY & Co